Rani Therapeutics Holdings, Inc.
RANINasdaq
$0.70
↑ +4.1%Jul 17 close · end-of-day
Price
1Y↑ +70.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$125.5M
Enterprise Value
$115.9M
P/E
—
P/S
39.6
P/B
4.4
EV/EBITDA
—
PEG
—
FCF Yield
-13.6%
Dividend Yield
—
Revenue (TTM)
$3.2M
Net Income (TTM)
-$29.4M
Free Cash Flow (TTM)
-$17.1M
Gross Margin
—
Operating Margin
-1093.0%
Net Margin
-929.1%
ROE
-103.6%
ROIC
-145.8%
Debt / Equity
—
Net Cash
$9.6M
Return 1Y
+67.3%
Company profile
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly. RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis, RT-102, a parathyroid hormone that is in preclinical studies for osteoporosis.
- CEO
- Talat Imran
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 110
- Headquarters
- California
- Website
- ranitherapeutics.com
Earnings
RANI Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.7M↑ +893.0%
Diluted EPS-$0.04↓ -81.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $462,000.00 | $2.7M | $0.00 | $0.00 | $1.0M | $1.6M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$16.5M | -$51.6M | -$63.5M | -$66.1M | -$53.3M | -$38.3M |
| Net income | — | -$8.3M | -$30.6M | -$34.0M | -$30.0M | -$29.7M |
| Diluted EPS | — | -$0.43 | -$1.28 | -$1.33 | -$1.05 | -$0.45 |
| Operating cash flow | -$15.0M | -$32.2M | -$46.5M | -$51.2M | -$35.5M | -$18.7M |
| Free cash flow | -$16.2M | -$32.8M | -$48.1M | -$52.5M | -$35.8M | -$18.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -3581.0% | -1899.1% | — | — | -5186.2% | -2346.0% |
| Net margin | — | -306.6% | — | — | -2920.0% | -1817.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $1.0M | $172,000.00 | $0.00 | $0.00 | $1.5M | $1.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$12.5M | -$11.8M | -$15.0M | -$12.0M | -$10.5M | -$7.3M | -$8.5M | -$8.3M |
| Net income | -$6.8M | -$6.8M | -$8.9M | -$7.3M | -$6.7M | -$5.4M | -$10.3M | -$7.0M |
| Diluted EPS | -$0.26 | -$0.24 | -$0.26 | -$0.22 | -$0.18 | -$0.12 | $0.07 | -$0.04 |
| Operating cash flow | -$9.0M | -$8.4M | -$8.7M | -$8.1M | -$5.8M | -$5.1M | $294,000.00 | -$6.5M |
| Free cash flow | -$9.1M | -$8.5M | -$8.7M | -$8.2M | -$5.8M | -$5.1M | $294,000.00 | -$6.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | -1455.0% | -6984.3% | — | — | -584.2% | -488.2% |
| Net margin | — | — | -870.3% | -4223.3% | — | — | -705.3% | -411.8% |
Company news
Jul 20, 2026
Jun 29, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-10-23 | IMRAN MIR A | Buy | 2,083,334 | $0.61 | $1.3M | filing |
| 2025-10-21 | South Cone Investments Limited Partnership | Sale | 4,000,000 | $2.77 | $11.1M | filing |
| 2025-10-20 | South Cone Investments Limited Partnership | Sale | 1,923,000 | $2.41 | $4.6M | filing |
Latest 3 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.